Neuroscience

Four compounds show promise against Alzheimer’s

Passage Bio plans Phase 1/2 trial of gene therapy in humans based on preclinical results

Natural compound attacks Alzheimer’s disease early

Potential biomarker for Alzheimer’s, Parkinson’s and other diseases can be found in the eye

Havn Life Sciences, along with the MIND Foundation, supports the first modern psilocybin depression study in Germany

Researchers have found that dimethyltryptamine promotes neurogenesis

The Society for Nueroscience meeting may have been called off this year, but DDN has a large roundup of recent news of neurological R&D to share in its place, from aging insights via sea urchins to machine learning advances to putting antibodies to work in treating neurodegeneration (and more)

Market research suggests that neurology-related pharma and biotech R&D is going to be dominated by Alzheimer's disease for some time

Psychedelics like psilocybin, DMT, and LSD are increasingly welcomed in behavioural and psychiatric research, with implications that extend well beyond neuroscience. This webinar will delve into efforts to transform anecdotal evidence into supported medical interventions through systematic research and controlled clinical trials.

Adding Optune to chemotherapy more than doubled five-year overall survival rate